# psoriasis - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 2
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 31495
- Completion tokens: 7635
- Reasoning tokens: 3943
- Total tokens: 39130
- API requests reported: 2
- Elapsed seconds: 88.991
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 2/5; original repeat 2; model vendor: xAI

---
**Overall biological interpretation**  
The transcriptomic profile of psoriatic lesional skin versus normal control skin is dominated by strong upregulation (90 of 100 genes) of genes linked to innate immunity, epidermal hyperproliferation, and cytokine-driven inflammation. This pattern reflects the core pathobiology of psoriasis—keratinocyte activation and antimicrobial peptide production in response to microbial or inflammatory cues—coupled with dysregulated skin barrier formation. The data integrate signals from defensin family members, IL-36/IL-17 family cytokines, S100 alarmin proteins, and cornified envelope components, collectively pointing to a self-amplifying loop of local innate immune activation and epidermal remodeling that distinguishes lesional from non-lesional or healthy skin.

**Core biological programs**  

**Antimicrobial Humoral Response**  
Direction: upregulated  
Major supporting genes: DEFB4A, DEFB4B, DEFB103A, DEFB103B, KYNU  
Pathway: GO:0019730 Antimicrobial Humoral Response; KEGG: Staphylococcus aureus infection  
Supporting genes collectively encode antimicrobial peptides and associated enzymes that are dramatically induced in keratinocytes of psoriatic plaques, consistent with heightened innate defense against microbial triggers.  
Strength of evidence: multiple independent genes with extreme FDRs in the input dataset plus pathway ontology; limitations include possible contribution from skin microbiome rather than direct disease causality.  

**IL-36/IL-17 Cytokine Signaling**  
Direction: upregulated  
Major supporting genes: IL36A, IL36G, IL36RN, IL19, IL20, IL26, TNIP3  
Pathway: KEGG IL-17 signaling pathway; Cytokine-cytokine receptor interaction  
The IL-36 family and related cytokines (plus their receptors and modulators) drive NF-κB activation, chemokine production, and keratinocyte proliferation, establishing a feed-forward inflammatory circuit central to psoriasis.  
Strength of evidence: multiple genes across the dataset plus direct pathway records; limitations include IL36RN upregulation possibly representing a compensatory feedback mechanism rather than unidirectional causation.  

**Cornified Envelope Formation**  
Direction: upregulated  
Major supporting genes: SPRR2A, SPRR2B, SPRR2D, SPRR2E, SPRR2F, SPRR2G, LCE3A, LCE3D, KRT6A, PI3  
Pathway: Reactome: Formation of the cornified envelope (R-HSA-6809371)  
Genes encode structural proteins and enzymes that strengthen the thickened stratum corneum characteristic of hyperproliferative epidermis in psoriasis.  
Strength of evidence: clustered genes within the dataset plus tissue-specific keratinocyte expression records; limitations include SPRR overexpression also marking normal differentiation, reducing specificity to disease.  

**S100 Protein-Mediated Innate Inflammation**  
Direction: upregulated  
Major supporting genes: S100A7, S100A8, S100A12, S100A7A  
Pathway: GO: Response to Lipopolysaccharide; innate immune response  
S100 proteins function as damage-associated molecular patterns that amplify keratinocyte activation and recruit additional immune cells in lesional skin.  
Strength of evidence: multiple genes in the input list plus ontology overlap with antimicrobial and cytokine programs; limitations include their broad, non-psoriasis-specific roles in any inflammatory context.

**Key genes and interaction modules**  
- **IL36A** (upregulated, log2FC 11.37): central driver of the IL-36/IL-17 program; proposed regulatory interaction with IL36RN and IL36G via shared pathway membership.  
- **S100A12** (upregulated, log2FC 8.33): alarmin linking innate inflammation to S100 family module; co-expression with S100A7/A8.  
- **SPRR2A** (upregulated, log2FC 7.31): marker of cornified envelope; pathway co-membership and co-expression with SPRR2B/D/E/F/G.  
- **DEFB4A** (upregulated, log2FC 11.18): antimicrobial peptide effector in humoral response program; indirect relationship via shared keratinocyte expression.  
- **IL19** (upregulated, log2FC 7.58): cytokine within IL-36/IL-17 module; regulatory interaction with IL26 and IL20 via shared receptor complexes (STRING).  
- **IL36RN** (upregulated, log2FC 3.01): IL-1 family antagonist in cytokine signaling; regulatory interaction with IL36A/G.  
- **KRT6A** (upregulated, log2FC 4.30): epidermal differentiation marker in cornified envelope program; co-expression with SPRR genes.  
- **CXCL13** (upregulated, log2FC 5.89): chemokine driving immune cell recruitment; indirect relationship via cytokine-cytokine receptor interaction.  
- **BTC** (downregulated, log2FC −4.30): epidermal growth factor-like factor potentially counteracting proliferation; possible indirect relationship with upregulated SPRR/KRT genes.  
- **LOC107984452** (downregulated, log2FC −6.25): uncharacterized gene of unknown role in current programs; no proposed interactions.

**Validation priorities**  
**Mechanistic hypothesis**  
Why prioritized: multiple genes in IL-36/IL-17 and antimicrobial programs with extreme statistical support in the dataset.  
Evidence provided: input log2FC/FDR values plus GO/KEGG pathway records.  
External evidence: literature links IL36A/DEFB genes to psoriasis but limited independent replication statistics.  
Next step: qPCR or single-cell RNA-seq validation of top genes in lesional versus non-lesional skin.  
Classification: supported hypothesis.

**Biomarker**  
Why prioritized: SPRR2A, S100A12, and DEFB4A show strongest fold-changes and overlap with known psoriasis gene sets.  
Evidence provided: dataset statistics plus tissue-specific expression records.  
External evidence: partial overlap with published psoriasis biomarker studies; no fully independent cohort statistics supplied.  
Next step: ELISA or multiplex assay of protein levels in skin biopsies or serum.  
Classification: supported hypothesis.

**Interaction/network hypothesis**  
Why prioritized: STRING and pathway co-membership data for SPRR cluster and IL-36 family.  
Evidence provided: input dataset plus network annotation records.  
External evidence: co-expression of SPRRs and IL-36 components in keratinocytes is established, but direct physical interactions are sparse.  
Next step: CRISPR-based disruption of key network edges in keratinocyte models.  
Classification: exploratory hypothesis.

**Confounding or composition check**  
Why prioritized: skin contains mixed keratinocytes and immune infiltrates.  
Evidence provided: dataset statistics.  
External evidence: no deconvolution performed; immune-related genes may partly reflect cell-type shifts rather than intrinsic keratinocyte changes.  
Next step: single-cell RNA-seq or flow-cytometry sorting to separate epidermal and dermal fractions.  
Classification: confounding or composition check.

**Therapeutic target**  
Why prioritized: IL-36 and cornified-envelope genes are central to programs.  
Evidence provided: input dataset plus pathway records.  
External evidence: no drug-target overlap or independent clinical statistics supplied for these exact genes.  
Next step: pharmacological inhibition studies in human skin equivalents.  
Classification: exploratory hypothesis.

**Evidence grounding**  
Major programs draw primary support from the input dataset statistics (log2FC, P, FDR) for all selected genes, supplemented by pathway/ontology evidence (GO, KEGG, Reactome) and tissue-specific expression records. Protein interaction evidence is limited to STRING co-expression or receptor-sharing relationships, which are regulatory or pathway-level rather than direct physical. Disease-association evidence is contextual (psoriasis lesional skin) and partially overlaps with published literature, but sources are not independent of the input cohort. No independent-cohort statistics for replication were supplied. All conclusions remain hypothesis-level given the absence of external replication.

**Limitations and alternative explanations**  
1. Cell-composition differences: psoriatic skin is infiltrated by immune cells; many upregulated genes (defensins, S100s, chemokines) may reflect leukocyte influx rather than keratinocyte-intrinsic changes—distinguishable by single-cell deconvolution.  
2. Disease stage/severity variability: plaque age and activity not specified; gene expression can fluctuate with lesion chronicity.  
3. Potential batch/platform effects: although not flagged in the ledger, unmeasured technical covariates could inflate fold-changes.  
4. Association-versus-causation ambiguity: strong associations do not establish causality without functional perturbation.  
5. Broad pathway enrichment: GO terms such as “response to lipopolysaccharide” capture general innate immunity rather than psoriasis-unique mechanisms; keratinocyte-specific validation would refine specificity.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=8, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
